Related Experiment Video
Updated: Aug 14, 2025
A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
Published on: November 3, 2016
The Reform of the Newborn Screening Policy: Spinal Muscular Atrophy
1Dr. Jur. at the University of Szeged (Hungary, 2017); LL.M. at the University of Toledo (USA) and University of Szeged (Hungary, 2014) in American law; LL.M. at the University Paris 2 Panthéon-Assas (France, 2018) in French, European, and International Business Law; and Ph.D. candidate at the University of Bourgogne Franche-Comté (France) in contracts and international trade law.
Insights
Spinal Muscular Atrophy (SMA) is a rare genetic disease affecting muscles. Early newborn screening allows timely treatment, improving health outcomes for affected infants and aiding family planning.
Area of Science:
- Genetics
- Neurology
- Pediatrics
Background:
- Spinal Muscular Atrophy (SMA) is a severe hereditary genetic disorder affecting muscle development.
- It impacts approximately 1 in 10,000 newborns, with a significant mortality rate before age two.
- Early diagnosis and intervention are critical for managing SMA progression.
Purpose of the Study:
- To highlight the importance of newborn screening for Spinal Muscular Atrophy (SMA).
- To advocate for the implementation of national SMA screening policies.
- To emphasize the benefits of early detection for treatment and family planning.
Main Methods:
- The abstract discusses the genetic nature of SMA and its impact on muscle health.
- It references the availability of genetic carrier screening prior to pregnancy.
- It highlights the success of newborn screening programs in countries like the US.
Main Results:
- Newborn screening for SMA enables prompt access to life-saving treatments.
- Early detection significantly improves the long-term health and quality of life for infants with SMA.
- International examples, such as the US, demonstrate the effectiveness of established screening protocols.
Conclusions:
- Universal newborn screening for SMA is crucial for early intervention.
- Implementing national screening policies can enhance family planning and timely treatment access.
- Adopting comprehensive screening strategies will lead to better health outcomes for children with SMA.
Abstract:
One in every 10,000 children is born with SMA and half of them will not even live two years. It is a hereditary genetic disorder, where the muscles die. If it is discovered just after birth, newborns can get the newest medicines to maintain their health. Unlike some other common genetic diseases (e.g. Down-Syndrome), SMA can be screened prior to pregnancy to determine whether the parents are carriers. In Hungary, people have urged reform, due to the baby Zente case, whose story has reached millions. Australia and Germany have also discovered the need for screenings. However, the US has already introduced newborn screening for SMA, far ahead of European countries. National policies should adhere to the same path to contribute to appropriate family planning and to make the treatment available as soon as needed to provide a longer and better life for sick infants.
